Floatz logo

flt3 ligand

Myelodysplastic Syndrome (MDS)

Celldex TherapeuticsPhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Myelodysplastic Syndrome (MDS) cohort.

Asset / SponsorPhaseRating
Anti-Thymoglobulin, Rabbit
Peking University First Hospital
Phase 2/3BB
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 3BB
Muromonab-Cd3
St. Jude Children's Research Hospital
Phase 3BB
Zanubrutinib
Medical College of Wisconsin
Phase 2B
Montanide Adjuvant
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2B

View all 38 →

Same molecule, other indications

flt3 ligand is also rated in:

Recurrent Renal Cell CancerDormant
B
Indicative ·
57 / 100
View asset →
Chronic Lymphocytic Leukemia (CLL)Dormant
CCC
Indicative ·
55 / 100
View asset →
Indolent B-cell LymphomasDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →